If you have $20,000 ready to invest and want to keep things relatively low risk, ASX 200 blue chip shares can be a smart place to start.
These are established businesses with proven track records, strong competitive positions, and the ability to perform across different market conditions. They may not always grab headlines, but they are often the companies that quietly compound wealth over time.
Here are three ASX 200 blue chip shares that could be worth considering.
Cochlear Ltd (ASX: COH)
The first ASX 200 blue chip to consider is Cochlear.
It is a global leader in hearing implant technology and operates in a highly specialised market with strong barriers to entry.
What makes the business particularly attractive is the long-term nature of its customer relationships. Once a patient receives a cochlear implant, they often remain within the ecosystem for upgrades, servicing, and accessories.
This creates a recurring revenue stream that supports consistent growth.
With hearing loss becoming more prevalent globally and access to treatment expanding, Cochlear appears well placed to continue growing over the next decade and beyond.
ResMed Inc (ASX: RMD)
Another ASX 200 blue chip that could be worth considering is ResMed.
It operates in the sleep apnoea and respiratory care market, combining medical devices with digital health solutions.
Its business benefits from recurring revenue, as patients continue to purchase masks and accessories after adopting its devices. There are also strong structural tailwinds, including ageing populations and increasing awareness of sleep health.
While the share price has faced some volatility, the long-term outlook remains very positive and is supported by growing demand and ongoing innovation.
Wesfarmers Ltd (ASX: WES)
A third ASX 200 blue chip that could be a top pick for Aussie investors this month is Wesfarmers.
It is a diversified business with exposure to retail, industrial, and chemical operations, including well-known brands such as Bunnings, Kmart, Officeworks, and Priceline.
One of its key strengths is its ability to adapt and allocate capital effectively. Over time, management has shown a willingness to invest in growth areas while maintaining discipline.
This has helped the company deliver steady returns and maintain a strong market position.
For investors, Wesfarmers offers a blend of resilience and growth, arguably making it a dependable addition to a long-term ASX share portfolio.
The post 3 ASX 200 blue chip shares to buy with $20,000 appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear Limited right now?
Before you buy Cochlear Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- How to build a $500,000 ASX share portfolio step by step
- Top brokers name 3 ASX shares to buy next week
- How to build a Warren Buffett-inspired ASX share portfolio
- How to build massive wealth with ASX shares
- Why Dateline Resourcs, Northern Star, Rox Resources, and Wesfarmers shares are dropping today
Motley Fool contributor James Mickleboro has positions in Cochlear and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, ResMed, and Wesfarmers. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Cochlear and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.